Bio-Rad Laboratories Inc
$ 306.13
0.22%
02 Jun - close price
- Market Cap 8,174,598,000 USD
- Current Price $ 306.13
- High / Low $ 308.63 / 299.58
- Stock P/E 50.74
- Book Value 255.37
- EPS 6.02
- Next Earning Report 2026-07-30
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.02 %
- ROE 0.02 %
- 52 Week High 343.12
- 52 Week Low 218.14
About
Bio-Rad Laboratories, Inc. is an American developer and manufacturer of specialized technological products for the life science research and clinical diagnostics markets.
Analyst Target Price
$297.00
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-04-30 | 2026-02-12 | 2025-10-29 | 2025-07-31 | 2025-05-01 | 2025-02-13 | 2024-10-30 | 2024-08-01 | 2024-05-07 | 2024-02-15 | 2023-10-26 | 2023-08-03 |
| Reported EPS | 1.89 | 2.51 | 2.26 | 2.61 | 2.54 | 2.9 | 2.01 | 3.11 | 2.29 | 3.1 | 2.33 | 3 |
| Estimated EPS | 1.99 | 2.7 | 1.93 | 1.75 | 1.78 | 2.88 | 1.18 | 2.02 | 2.14 | 2.87 | 2.81 | 2.68 |
| Surprise | -0.1 | -0.19 | 0.33 | 0.86 | 0.76 | 0.02 | 0.83 | 1.09 | 0.15 | 0.23 | -0.48 | 0.32 |
| Surprise Percentage | -5.0251% | -7.037% | 17.0984% | 49.1429% | 42.6966% | 0.6944% | 70.339% | 53.9604% | 7.0093% | 8.0139% | -17.0819% | 11.9403% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-07-30 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | 1.75 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: BIO
2026-05-28 18:40:24
This SEC Filing (Form 144) for Bio-Rad Laboratories, Inc. (BIO) discloses a proposed sale of 700 shares of Class A Common stock by Alice Schwartz, acquired via donation on December 10, 2018. The aggregate market value of these shares is $219,296.44, to be sold on the NYSE on or after May 28, 2026, through Wells Fargo Clearing Services. The filing indicates a neutral impact and sentiment.
2026-05-24 11:09:49
Bio-Rad Laboratories (BIO) recently experienced a 16.2% weekly surge, prompting a re-evaluation of its stock valuation. According to Simply Wall St's analysis, the company scores 2 out of 6 on its valuation framework and is considered fairly valued by a Discounted Cash Flow (DCF) model, with an estimated intrinsic value of $288.45 per share against a market price of $287.74. However, its P/E ratio of 45.62x, compared to a Fair Ratio of 15.53x, suggests the stock is overvalued based on earnings multiples.
2026-05-23 00:09:54
This article aggregates trade ideas for Bio-Rad Laboratories, Inc. (BIO.B) from various traders on TradingView. Ideas range from long positions based on fundamental analysis and technical indicators like the 100 EMA and RSI, to short positions anticipated after a technical break. ValuEngine also upgraded its rating for BIO.B to a BUY.
2026-05-21 05:39:43
Elliott Investment Management has acquired a significant stake in Bio-Rad Laboratories, signaling potential pressure for operational, governance, or portfolio changes. This move comes as Bio-Rad faces a mixed share price record and holds a substantial stake in Sartorius. Investors are anticipating proposals from Elliott regarding operational shifts, board changes, or actions concerning Bio-Rad’s Sartorius holding, alongside renewed analyst interest and expectations for margin improvements.
2026-05-20 03:40:15
Activist investor Elliott Investment Management has acquired a significant stake in Bio-Rad Laboratories, Inc. and plans to advocate for improved share performance. Bio-Rad's substantial investment in Sartorius, valued at approximately $5 billion, is a key focus for Elliott, representing a significant portion of Bio-Rad's market capitalization. Despite a recent decline in Bio-Rad's share price and slight earnings miss, the company's turnaround potential and the value of its Sartorius stake could make it an attractive acquisition target.
2026-05-20 03:38:58
RBC Capital has restarted coverage of Bio-Rad Laboratories (BIO) with an Outperform rating, anticipating improved margins under new leadership and a sales recovery by 2027. This positive outlook is supported by recent share repurchases and strategic platform rollouts, reinforcing the importance of margin repair as a key near-term catalyst. However, investors should remain aware of potential risks from prolonged weakness in research and clinical demand.
